Indicators of high blood sugar levels, particularly stress hyperglycemia ratio (SHR), may predict clinical worsening in people with idiopathic pulmonary arterial hypertension, a study in China indicates. Clinical worsening was defined as the first occurrence of lung transplant, being rehospitalized due to heart failure, or death from any cause.
LungFit PH, Beyond Air’s device for administering nitric oxide therapy, has received European CE mark approval for persistent pulmonary hypertension in newborns (PPHN). This approval allows the company to market the device in the European Union and all other countries that recognize this certification, and also extends its…
Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, a lung transplant, or hospitalization among adults with pulmonary arterial hypertension (PAH) at a high risk of dying enrolled in a Phase 3 clinical trial. These top-line findings in the ongoing ZENITH trial (NCT04896008), testing the Merck…
Sildenafil is generally more effective than bosentan at controlling blood pressure and reducing the need for supplemental oxygen in infants with persistent pulmonary hypertension of the newborn (PPHN), a study shows. The study, “Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn:…
High levels of a small RNA molecule in the blood may be a marker of pulmonary arterial hypertension (PAH) in people with congenital heart diseases, a new study reveals. The study, “Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,”…
Platelets, or cell fragments in blood that help stop or prevent bleeding, tend to cluster in lung blood vessels of people with decompensated pulmonary hypertension (PH), a lung disease characterized by sudden worsening of clinical signs of right heart failure, followed by other severe complications, a study has found.
A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…
Cereno Scientific has secured loan financing to continue developing CS1, its lead therapeutic candidate for pulmonary arterial hypertension (PAH). The funds, totaling at least 250 million Swedish crowns (nearly $23 million), will help the company reach its milestones into 2026. This includes the U.S. Food and Drug Administration…
A Phase 2 clinical trial of TX45, Tectonic Therapeutic’s investigational therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has begun enrolling eligible patients. The Phase 2 study, called APEX (NCT06616974), is expected to recruit up to 180 adults with PH-HFpEF, ages…
Adding Uptravi (selexipag) to standard-of-care therapy within six months of starting treatment may reduce the risk of hospitalization and disease progression in people with pulmonary arterial hypertension (PAH), a study found. The study, “Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension,” was…
Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…
Abnormalities in blood levels of various microRNAs (miRNAs) — small RNA molecules that regulate other genes in protein production — may contribute to the development and progression of chronic thromboembolic pulmonary…
Get regular updates to your inbox.